Table 3.

Predictive value of mid-therapy ¹⁸F-FDG PET scanning for outcome in NHL (excluding risk-adapted studies)

Series	Year	n	Rituximab (n)	Median follow-up (months)	No. of cycles before PET	PPV (%)	NPV (%)	Sens (%)	Spec (%)	Survival endpoint	PET positive outcome (%)	PET negative outcome (%)
Jerusalem et al 31	2000	28	No	17.5	2-5	100	67	42	100	2-year PFS	0	62
Mikhaeel et al 21	2000	23	No	30	2-4	88	100	100	92	NR	NR	NR
Spaepen et al 32	2002	70	No	36	3-4	100	100	85	100	2-year PFS	4 ¥	85 ¥
Kostakoglu et al 24	2002	30 †	No	19	1	87	87	87	87	18-month PFS	10 ¥	75 ¥
Mikhaeel et al 33	2005	102	Some NR	24	2-3	71	90	88	75	5-year PFS	16	89
Haioun et al 34	2005	90	Yes (37)	24	2	44	90	76	70	2-year EFS	43	82
Querellou et al 35	2006	48 §	Yes (21)	16	2-4	83	83	63	94	2-year EFS	20	80
Fruchart et al 36	2006	35	Yes (26)	19	2-3	60	95	90	76	2-year EFS	30	85
Ng et al 37	2007	44	Yes (18)	28	2-4	67	89	67	89	5-year-PFS	29	90
Han et al 29	2008	40	Yes	24	2-4	33	68	33	68	2-year PFS	77	83
Cashen et al‡ 38	2008	50	Yes	15	2-3	25	85	60	53	15-month PFS	70 ¥	90 ¥
Pregno et al‡ 39	2008	42	Yes	22	2	NR	NR	NR	NR	2-year PFS	75	71
Gigli et al‡ 40	2008	42	Yes	15	3	43	93	75	76	2-year EFS	55	90
Dupuis et al41	2009	103	Yes (50)	53	4	71	79	52	89	5-year EFS	36	80

^†13 HL

^§24 HL

^¥Estimated from Kaplan-Meier PFS curve

^‡These data were presented in abstract form only

Abbreviations: ¹⁸F-FDG PET: ¹⁸Flourine-Flourodeoxyglucose Positron Emission Tomography, NHL: Non-Hodgkin Lymphoma, PPV: Positive Predictive Value, NPV: Negative predictive value, Sens: Sensitivity, Spec: Specificity, PFS: Progression-Free Survival, RFS: Relapse-Free Survival, EFS: Event-Free Survival, NR: Not Reported, HL: Hodgkin Lymphoma.